1. HBW Insight
  2. >>Wellness
  3. >>Business
  4. >>Marketing & Advertising

Providing High Value, OTC Drugs Deserve Higher Profile In Health Care – CHPA

 
• By Malcolm Spicer

While Rx drug pricing is under attack by Congress, White House and consumer and public health advocacy groups, OTC drugs' value isn't gaining a higher profile. "Our health care system undervalues the contribution of our industry's products," says CHPA chief Scott Melville. Trade group conducts “Value of OTC Medicines" study for reasons including raising the profile of consumer health products in the US health care system.

The Consumer Healthcare Products Association's latest survey to quantify the value of OTC drugs to US health care suggests total annual savings o the system increased by nearly $45bn since its previous research.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

More from Business

Good News? 90-Day Pause On Most Tariff Changes – Bad News? 125% Rate Imposed Against China

 
• By Malcolm Spicer

US businesses across industry sectors remain apprehensive about higher tariffs going into effect on imports from China after three-month pause allowed on other changes.

KKR Expands Health & Beauty Portfolio With Deal For Sweden’s Karo

 
• By Tom Gallen

Consumer health player Karo is changing hands from EQT to KKR in a deal thought to value the Stockholm-based firm at over €2.5bn.

Clasado Divests Bimuno Prebiotic Consumer Brand To UK’s Eleat

 
• By David Ridley

Eleat's acquisition encompasses Clasado's Bimuno finished supplement product line and customer base, but not its Bimuno GOS proprietary galactooligosaccharide prebiotic ingredient.